S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EKSO

Ekso Bionics (EKSO) Stock Price, News & Analysis

$1.36
-0.06 (-4.23%)
(As of 03/28/2024 ET)
Today's Range
$1.28
$1.46
50-Day Range
$1.32
$2.50
52-Week Range
$0.62
$3.13
Volume
357,021 shs
Average Volume
213,277 shs
Market Capitalization
$24.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.25

Ekso Bionics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
580.1% Upside
$9.25 Price Target
Short Interest
Healthy
0.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Ekso Bionics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.49) to ($0.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.70 out of 5 stars

Medical Sector

473rd out of 938 stocks

General Industrial Machinery, Industry

3rd out of 10 stocks

EKSO stock logo

About Ekso Bionics Stock (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.

EKSO Stock Price History

EKSO Stock News Headlines

Ekso Bionics (NASDAQ:EKSO) Upgraded to Hold at StockNews.com
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Recap: Ekso Bionics Holdings Q4 Earnings
Ekso Bionics earnings preview: what to expect
Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc (EKSO)
See More Headlines
Receive EKSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/29/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
General industrial machinery,
Sub-Industry
N/A
Current Symbol
NASDAQ:EKSO
Previous Symbol
OTCMKTS:EKSOD
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.25
High Stock Price Target
$9.25
Low Stock Price Target
$9.25
Potential Upside/Downside
+580.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,200,000.00
Pretax Margin
-83.14%

Debt

Sales & Book Value

Annual Sales
$18.28 million
Book Value
$0.85 per share

Miscellaneous

Free Float
16,560,000
Market Cap
$24.34 million
Optionable
Optionable
Beta
1.65
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Scott G. Davis (Age 54)
    CEO & Director
    Comp: $535.8k
  • Mr. Jerome Wong (Age 50)
    Corporate Controller, Corporate Secretary & CFO
    Comp: $356.81k
  • Mr. Jason C. Jones
    Chief Operating Officer
  • Ms. Rachael Anderson
    Global Director of Marketing & Strategic Growth
  • Mr. Anthony Pratt
    Vice President of Sales
  • Ms. Ann Cookson
    Human Resources Director
  • Ms. Foon Lim Chwee
    President of APAC
  • Mr. Stephan Aderhold
    Senior VP & GM of EMEA

EKSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Ekso Bionics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings
or view top-rated stocks.

What is Ekso Bionics' stock price target for 2024?

1 analysts have issued 12 month target prices for Ekso Bionics' shares. Their EKSO share price targets range from $9.25 to $9.25. On average, they expect the company's stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 580.1% from the stock's current price.
View analysts price targets for EKSO
or view top-rated stocks among Wall Street analysts.

How have EKSO shares performed in 2024?

Ekso Bionics' stock was trading at $2.50 at the start of the year. Since then, EKSO stock has decreased by 45.6% and is now trading at $1.36.
View the best growth stocks for 2024 here
.

When is Ekso Bionics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our EKSO earnings forecast
.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings results on Monday, March, 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.11. The business had revenue of $4.85 million for the quarter, compared to analyst estimates of $4.80 million. Ekso Bionics had a negative net margin of 83.14% and a negative trailing twelve-month return on equity of 90.80%. During the same period in the prior year, the company earned ($0.24) EPS.

When did Ekso Bionics' stock split?

Shares of Ekso Bionics reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Ekso Bionics issued on next quarter's earnings?

Ekso Bionics issued an update on its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.7 million-$4.9 million, compared to the consensus revenue estimate of $4.6 million.

What other stocks do shareholders of Ekso Bionics own?
Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (1.06%), Kent Lake Capital LLC (0.95%), Strategic Wealth Investment Group LLC (0.37%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends
.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EKSO) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners